
Verigat2.5 mg
ACME Laboratories Ltd.
Vericiguat is indicated, in combination with other heart failure therapies, to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart…
Vericiguat is indicated, in combination with other heart failure therapies, to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction below 45%, following a recent episode of decompensation requiring hospitalization or outpatient intravenous diuretic treatment.
The dose of Vericiguat is individualized and titrated gradually to minimize the risk of symptomatic hypotension.
| Step | Dose | Duration |
|---|---|---|
| Starting dose | 2.5 mg once daily (with food) | Approximately 2 weeks |
| First titration step | 5 mg once daily, if the previous dose is tolerated | Approximately 2 weeks |
| Target maintenance dose | 10 mg once daily, if the previous dose is tolerated | Long-term, as advised by physician |
If a patient does not tolerate a dose increase due to symptomatic hypotension, the physician may delay titration or temporarily reduce the dose of Vericiguat. It should be taken at approximately the same time each day, with food, to enhance and maintain consistent absorption.
The most commonly reported side effects of Vericiguat include:
Patients taking Vericiguat should contact their physician if they experience persistent dizziness, fainting, unusual fatigue, or symptoms suggestive of low blood pressure.
Vericiguat is contraindicated in the following situations:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.